Prostate Cancer

1st Edition

Dana-Farber Cancer Institute Handbook

Editors:

  • Print ISBN 9780723434368

Key Features

  • Comprehensive coverage - from risk and prevention, and screening and diagnosis, through to treatment options (chemotherapy, radiation therapy, biological response modifiers)
  • Attractively designed aids with instant access to the information
  • Contains useful algorithms to aid management decisions
  • Discusses practical management of problems in cancer therapy including fever, vomiting, alopecia, fatigue, pain and cachexia
  • Provides practical advice regarding drug administration
  • Linked to the hugely successful Dana-Farber Atlas of Diagnostic Oncology

Table of Contents

Introduction

The role of molecular probes and other markers in the diagnosis and characterization of malignancy

Prostate cancer: epidemiology, histology, diagnosis and staging

Prostate cancer therapy

Systemic and mucocutaneous reactions to chemotherapy

Details

No. of pages:
144
Language:
English
Copyright:
© 2007
Published:
Imprint:
Mosby Ltd.
Print ISBN:
9780723434368

About the editors

Arthur Skarin

Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women’s Hospital and Dana-Farber Cancer Institute (DFCI) in 1970. He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School. He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women’s Hospital General Clinical Research Center (GCRC) and DFCI. Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists. He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books.

Affiliations and Expertise

Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA; Senior Attending Physician, Dana-Farber Cancer Institute, Boston, MA, USA

William Oh

Affiliations and Expertise

Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

John Logue

Affiliations and Expertise

Consultant Medical Oncologist, Christie Hospital NHS Trust, Manchester, UK